Pharma BD Deal Intelligence

Quince Therapeutics, Inc. / Orphai Therapeutics Inc.

2026 · Acquisition/Merger · Complete

Quince Therapeutics acquired Orphai Therapeutics, a clinical-stage biotech, bringing in lead asset LAM-001 (inhaled rapamycin) for rare pulmonary diseases including PH-ILD and bronchiolitis obliterans syndrome. Concurrent private placement of up to $187 million ($115M upfront plus up to $72M warrants) led by Balyasny Asset Management.

Key facts

• Announced May 18, 2026
• Closed May 18, 2026
• Deal type Acquisition/Merger
• Therapeutic area pulmonary hypertension associated with interstitial lung disease (PH-ILD); bronchiolitis obliterans syndrome (BOS) post-lung transplant
• Indications pulmonary hypertension associated with interstitial lung disease (PH-ILD); bronchiolitis obliterans syndrome (BOS) post-lung transplant
• Key assets LAM-001 (inhaled rapamycin)
• Mechanism mTOR inhibitor (inhaled rapamycin formulation)

← Browse all deals  ·  How we score deals